Cambrex Corporation, a manufacturer of generic active pharmaceutical ingredients (APIs) and finished dosage forms, is investing another $1 million at its High Point, NC site to fit out 1,300 square feet of analytical laboratory space.
At the facility, Cambrex produces complex APIs and intermediates requiring multi-step synthetic processes in batch sizes from milligrams to 100kg to support clinical trials from Phase I to Phase III.
The expansion and fit out will include the installation of an additional 10 ultra-performance liquid chromatography instruments, the addition of nine chemical research and development scientists, and six analytical research and development scientists.
The investment follows the new $3.2 million, 11,000-square-foot analytical laboratory, completed in April.
The site is licensed with the U.S. Drug Enforcement Administration (DEA) to manufacture Schedule II to Schedule V controlled substances. The acquisition enhanced Cambrex’s portfolio of small molecule API services and complements its large scale, multi-purpose manufacturing facilities in the U.S. and Europe.
This latest expansion at the 35,000-square-foot facility brings the investment at the site to more than $9 million since the acquisition of PhamaCore by Cambrex in 2016. It is set to be completed by year-end, according to the company.
(Source: Cambrex Corporation)
